Trial Profile
A Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients with Glioblastoma (GBM)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- 08 Apr 2022 Primary endpoint (Overall Survival Rate at 6 Months (OS-6) as Estimated Using the Kaplan-Meier Method (Cohort C)) has not been met as per results published in the Clinical Cancer Research
- 08 Apr 2022 Primary endpoint (Progression-free Survival Rate at 6 Months (PFS-6) as Estimated Using the Kaplan-Meier Method (Cohorts B, B2, and B3)) has not been met as per results published in the Clinical Cancer Research
- 08 Apr 2022 Primary endpoint (Overall Survival Rate at 12 Months (OS-12) as Estimated Using the Kaplan-Meier Method (Cohort A)) has not been met as per results published in the Clinical Cancer Research